Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study will be a randomized, double-blind, placebo-controlled crossover study to assess
the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to
placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.